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The proto-oncoprotein MET is a receptor tyrosine kinase that plays a key role in cancer cell growth
and invasion. We have used fluorescence-tagged antibodies to activate MET in live serum-starved
glioblastoma cells and monitor the fate of antibody-bound MET receptor in single cell-based assays. We
found that the antibodies induced rapid and transient formation of highly polarized MET clusters on the
plasma membrane and promoted the activation of MET, resembling the initial effects of binding to its
ligand, HGF. However, the antibody-induced clustering and activation of MET led to the rapid removal
of the receptor from cell surface and altered its intracellular processing, resulted in rapid degradation of
the receptor. Consequently, while cells pre-treated with HGF remain competent to respond to further
HGF stimulation, cells pre-treated with antibodies are refractory to further HGF stimulation due to
antibody-mediated MET depletion. Removal of MET by sustained treatment of antibodies blocked
cancer cell migration and invasion. Our studies reveal a novel mechanism to alter the recycling process
of MET in glioblastoma cancer cells by promoting the receptor degradation through a proteasomesensitive and lysosome-dependent pathway through the ligand-independent activation of MET using
anti-MET antibodies.
The Met oncogene was originally identified as a chromosomal translocation fusion gene, which encode the
oncogenic TPR-MET fusion protein in a chemically transformed human osteosarcoma-derived cell line1. The
TPR-MET fusion oncogene expresses a constitutively active MET receptor tyrosine kinase (RTK) activity due
to the dimerization of the leucine-zipper domain in the TPR (Translocated Promoter Region) moiety of the
fusion protein2. The MET (also called c-MET) RTK is normally expressed in various cells of epithelial origins
or fibroblasts, and is essential for embryonic development, mitogenesis and morphogenesis of various tissues
such as skeletal muscle, limb, and neural crest development3,4. The MET RTK is activated by the binding of its
cognate ligand, hepatocyte growth factor (HGF), which induces the phosphorylaton of two tyrosine residues,
tyrosine-1234 and tyrosine-1235 (Y1234/Y1235) of the catalytic loop of the kinase domain5. MET activation
mobilizes the coordinated invasive cell growth program by promoting cell proliferation, survival, migration, and
morphogenesis3,4.
Altered expression of MET is associated with various malignancies. Amplification of the Met gene is identified in medulloblastoma, gastric and esophageal carcinomas, and non-small-cell lung (NSCL) carcinoma with
acquired resistance to epidermal growth factor receptor (EGFR) inhibitor, whereas activating mutations of MET
are associated with sporadic papillary renal cancer, childhood hepatocellular carcinoma and gastric carcinoma6.
The expression of MET is also aberrantly up-regulated in many human malignancies including glioblastoma
multiforme (GBM)7, the most aggressive and therapeutically difficult brain tumor8. In normal cells, HGF-induced
MET activation is a tightly regulated process9. After ligand binding, MET is internalized via endocytosis and the
tyrosine-phosphorylated receptor is recognized by CBL ubiquitin E3 ligase to target MET to multivescular bodies
for subsequent degradation in lysosomes9. Notably, certain mutations in the kinase domain of MET, originally
identified in human renal papillomas, allow the receptor to constitutively recycle back to the cell surface, and
these mutations lead to stronger signaling activities10. Abnormal activation of MET is responsible for resistance
1

School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, Guangdong,
China. 2Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, 89154-4003,
USA. Correspondence and requests for materials should be addressed to H.S. (email: hong.sun@unlv.edu)

SCientifiC REPOrTS |

(2019) 9:1988 | https://doi.org/10.1038/s41598-018-36963-3

1

www.nature.com/scientificreports/
to targeted therapies against VEGFR (vascular endothelial growth factor receptor) in GBM11,12 and inhibitors of
the EGFR in lung cancers13,14. Over-expression or ligand-mediated activation of the MET signaling pathway is
an established mechanism of resistance towards the targeted therapies against members of EGFR subfamily of
RTKs6.
Since the high level expression of MET is correlated with poor prognosis of various cancers, MET serves as
an excellent target for cancer therapy. Various approaches, such as the development of small molecular chemical
inhibitors or specific monoclonal antibodies, have been explored to inhibit the RTK activity of MET or to block
the interaction between the MET receptor and the ligand, HGF, in a wide array of cancers15,16. An one-armed
monovalent 5D5 antibody has been developed17–19 that binds to the monomeric MET protein on the cell surface
and blocks the binding of HGF to the receptor without induction of the down-regulation of the MET receptors. A non-activating monoclonal antibody, LY2875358, was recently reported20. This antibody can prevent the
MET receptor to interact with HGF, as well as to trigger receptor downregulation20. Another bivalent antibody,
SAIT301, which does not activate the RTK activity of MET, was also shown to cause the downregulation of the
MET protein after an extended treatment21. It appears that LY2875358 and SAIT301 employ different cellular
processes to down-regulate MET receptors, although a direct comparison of these two antibodies is lacking.
These studies suggest that the MET receptor, with its unique structural or conformational determinants, may be
manipulated through binding with antibodies to target the receptors to degradation.
We have recently found that the MET receptor is often complexed with AXL, another important RTK, in glioblastoma and breast cancer cells22. HGF stimulation induces an enhanced formation of the MET-AXL complex to
promote the MET-AXL co-clustering on the plasma membrane22. Our findings reveal that HGF-dependent clustering of the MET-AXL complex is required for the MET-mediated cell signaling. In addition, we have recently
shown that the cell surface delivery of MET from Golgi is a highly regulated process which is very sensitive to the
lipid modification enzyme ASM (acid sphingomyelinase) in GBM cancer cells, suggesting that the total level of
cell surface MET is closely regulated by both newly synthesized MET from Golgi and recycling pool of MET23. In
this report, we have examined the cellular response to the ligand-independent activation of MET receptor on the
plasma membrane by antibody-mediated MET receptor clustering.

Results

Clustering of MET on the plasma membrane by APC-conjugated anti-MET antibodies.

Our
recent studies showed that the presence of MET RTK on the plasma membrane is dynamically regulated by
ceramides generated by ASM23 and HGF promotes the MET-AXL RTK complex formation on the plasma membrane22. To examine how MET is activated on the plasma membrane, we examined the distribution of the MET
protein in serum-starved human U373-MG glioblastoma cells, which express relatively high levels of MET protein23. To monitor the distribution of MET on the plasma membrane, we exposed live serum-starved cells to
mouse monoclonal anti-MET antibodies that were pre-conjugated with Allophycocyanin (APC), an intensely
bright phycobiliprotein that exhibits far-red fluorescence with high quantum yields. The advantage of using the
APC-conjugated MET antibody to immunostain live cells is that it only detected the plasma membrane-associated MET with high signal-to-noise ratio (Fig. 1A, top row). Interestingly, we found that addition of the APCtagged mouse monoclonal anti-MET antibody to the live serum-starved cells specifically detected MET proteins
in a highly “clustered” pattern on the plasma membrane in the live and serum-starved cells, while the control
APC-tagged mouse IgG did not produce any fluorescence signals in these cells (Fig. 1A, top panels).
We also monitored the distribution of total MET proteins after fixation and permeabilization of cells, using
rabbit anti-MET antibodies which are pre-conjugated to the Alexa Fluor 488 fluorophore, in a regular immunostaining procedure (Fig. 1A, middle row). The anti-MET antibodies (detected by Alexa Fluor 488 fluorescence) immunostaining revealed that MET is weakly and evenly distributed on the plasma membrane in the
serum-starved cells in the cells that exposed to the APC-IgG control antibody (Fig. 1A). The MET staining was
also present in the intracellular compartments. However, addition of the APC-conjugated anti-MET antibodies
appeared to cause a re-distribution of the MET protein on the plasma membrane that showed more polarized and
“clustered” immunostaining patterns of the receptors (Fig. 1A, middle row). The clustered areas of MET overlapped with that of the area occupied by the APC-conjugated MET antibodies on the plasma membrane (Fig. 1A,
bottom row), raising the possibility that the clustering of the MET protein on the plasma membrane is caused by
the APC-conjugated anti-MET antibodies.

Clustering and activation of MET on the plasma membrane by biotin-conjugated anti-MET
antibodies. The clustering of the MET protein on the plasma membrane in response to the APC-conjugated

MET antibody is reminiscent of T cell receptor activation by bivalent antibodies. T cell receptors have been
shown to be activated by the binding of bivalent antibodies to promote the oligomerization of the receptors and
subsequent assembly of multi-protein complexes, leading to the formation of a “patch” (also referred to as “cap”
or “cluster”) of the receptor complexes on the T cell membrane24. We have recently found that in various cancer
cells, MET can be induced to form clusters on the plasma membrane in response to its natural ligand HGF stimulation22. It is known that when MET receptors are bound by their cognate ligand HGF, receptors are induced to
form dimers and the kinase activity of MET is turned on by trans-phosphorylation of Y1234 and Y1235 within
the transactivation loop5. Since the addition of APC-conjugated anti-MET antibody to the serum-starved cells
showed the clustering of MET on the plasma membrane, we wondered whether clustering of the MET receptor
on the plasma membrane is accompanied by receptor dimerization and ligand-independent activation of the
MET RTK activity.
To test whether antibody-mediated cross-link of the receptor is sufficient to activate MET, we used an independent bivalent goat anti-MET antibody that was pre-conjugated to biotin. The conjugation of antibodies to
biotin allows the subsequent detection of the receptors by Streptavidin-labeled Brilliant Violet 421. Since the
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Figure 1. Antibody-mediated MET receptor crosslinking leads to the receptor clustering and patch formation on
the plasma membrane through activation of MET receptor. (A) Live U373-MG cells, which were serum starved
for three hours, were incubated with the APC-conjugated mouse monoclonal anti-MET antibody (1 μg/ml) (red)
or its isotype control, APC-conjugated, mouse IgG (1 μg/ml) for 7 minutes. Cells were then washed, fixed and
co-immunostained with an anti-MET antibody pre-conjuagted to Alexa Fluor 488, which detects the total MET
protein (green). Cells were imaged by confocal microscopy. Clusters (or patches) of the MET proteins on the plasma
membrane are indicated by arrows. (B) Live serum-starved U373-MG cells were treated with biotin-conjugated
goat anti-MET antibodies (2 μg/ml) or biotin-conjugated normal goat IgG antibodies (2 μg/ml) (control) for
7 minutes. Cells were then washed, fixed and immunostained with the Streptavidin-conjugated to Brilliant Violet
421 (BV421) to detect the biotin-conjugated antibodies (purple), a rabbit anti-Y1234/1235-phosphorylated MET
antibody for the activated MET protein (secondary antibody conjugated with Alexa Fluor 647, red), and an antiMET antibody pre-conjugated to Alexa Fluor 488 for total MET protein (green). (C) Serum-starved cells were left
untreated or stimulated with HGF (50 ng/ml) for 7 minutes. Cells were fixed and immunostained with a rabbit
antibody against Y1234/Y1235-phosphorylated MET for the activated MET protein (red) and with an anti-MET
antibody pre-conjugated with the Alexa Fluor 488 to detect total MET (green). (D) Serum-starved cells were treated
with the biotin-conjugated anti-MET antibody (2 μg/ml) and fixed at the various time points as indicated. Cells
were immunostained with strepavidin-conjugated to BV421 as in panel B. Scale bars in (A–C), 20 μm.

excitation of Brilliant Violet 421 by 405 nm laser induces a fluorescence maximum emission of 421 nm, it is possible to use three spectrum channels to simultaneously monitor and compare the distributions of biotinylated
antibodies (purple), the activated MET protein using a rabbit anti-phosphorylated Y1234/1235 antibody followed
by a secondary antibody conjugated with the Alexa Fluor 647 fluorophore (red), and subsequent detection of the
total MET proteins using an anti-MET antibody pre-conjugated to Alexa Fluor 488 (green). Our studies showed
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that exposure of live serum-starved cells to the biotinylated goat anti-MET antibody, but not a control biotinylated normal goat IgG, was sufficient to induce the clustering and patch formation of the MET proteins on the
plasma membrane (Figs 1B, S1A). These clustered MET areas represent the activated form of MET proteins since
they are phosphorylated at Y1234/Y1235, a pair of tyrosine residues that are autophosphorylated by the activated
MET RTK. Our studies indicate that the RTK activity of MET can be activated by receptor clustering through the
binding of the bivalent antibodies to the MET receptor on the plasma membrane in live serum-starved cells, and
such events can be detected at a single cell level.
In addition, the biotin-conjugated goat anti-MET antibodies also induced the cluster formation of the
phosphorylated MET receptor on the plasma membrane in other human glioblastoma cells such as T98G cells
(Fig. S1B), suggesting the ability to induce the activation and cluster formation by the biotinylated anti-MET
antibodies are not limited to U373-MG cells.

Clustering of MET on the plasma membrane by ligand binding.

The induction of clustered or
patched MET distribution on the plasma membrane by bivalent antibodies suggests that the MET RTK on the
plasma membrane may be activated through the similar manner by its natural ligand, HGF. Indeed, we have
recently found that addition of HGF to the serum-starved cells caused a rapid and dramatic change of the MET
distribution on the plasma membrane (Fig. 1C)22. We tested the effects of HGF at 50 ng/ml, the lowest concentration of HGF needed to maximally activate MET in U373-MG cells22, and the concentration is also in the range of
HGF known to be present in the tumor microenvironment in the melanoma samples carrying BRAF mutations25.
In serum-starved cells, there was no immunostaining signal when stained with the anti-phosphorylated Y1234/
Y1235 antibodies on the plasma membrane, suggest that MET is not activated (Fig. 1C). Addition of HGF to
the serum-starved cells induced a strong staining from antibodies specific for the Y1234/Y1235-phosphorylated
MET, which also exhibited the highly polarized and clustered phospho-MET staining patches that strongly overlapped with the staining with anti-MET antibodies (conjugated to Alexa Fluor 488) on the same cell (Fig. 1C).
Thus, the clustered staining of MET or phospho-MET represents the presence of the active MET forms on the
plasma membrane, which represent early events detectable at the single cell level during HGF-induced MET
receptor activation (Fig. 1C)22.

The clustering of the MET protein by the biotin-conjugated anti-MET antibodies occurred rapidly and transiently on the plasma membrane. To determine the temporal response of the MET pro-

teins towards specific antibodies, we monitored the cluster formation of the receptor on the plasma membrane at
various times after addition of the biotin-conjugated anti-MET antibodies to the serum-starved cells (Fig. 1D).
Our studies revealed that the antibody-activated clustering of the MET protein on the plasma membrane
occurred very rapidly and transiently (Fig. 1D). Addition of the biotin-conjugated anti-MET antibody between
2 to 5 minutes caused the patched clustering of the MET protein on plasma membrane in each cell (Fig. 1D). The
MET staining became a single bright spot or a strong patched area on the surface of each cell between 7–10 minutes after exposure to the biotin-conjugated anti-MET antibody, with some cells started to show internalized
biotin-conjugated anti-MET antibody at 10 minutes. Within 15–30 minutes, the MET staining disappeared from
cell surface, with concurrent strong intracellular staining inside of the cell, suggesting the internalization of the
antibody-MET complexes. These observations revealed that the antibody-mediated clustering of MET induced
the receptor activation and the activated receptors are quickly internalized, independent of the ligand binding.

Both APC- or biotin-conjugated anti-MET antibodies transiently activate the MET RTK signaling process. We have further biochemically examined and compared the ligand- and antibody-induced

MET activation. In serum-starved cells, MET was not phosphorylated on Y1234/Y1235 (p-Y1234/Y1235), as
revealed by Western blotting analysis. Addition of HGF to the serum-starved cells promoted the phosphorylation of Y1234/Y1235 on MET within 7 minutes (Fig. 2A). In addition, HGF initiated a cascade of MET signaling
events, including the phosphorylation and activation of downstream kinases such as AKT (Fig. 2A). We found
that addition of the APC- and biotin-conjugated anti-MET antibodies, but not the control normal IgG which
were similarly conjugated to APC or biotin, to the live serum-starved cells, each induced the phosphorylation of
Y1234/Y1235 on MET within 7 minutes (Fig. 2B,C). To determine whether the activation of MET by these conjugated antibodies is not limited to human U373-MG glioblastoma cells, we also tested the response of other human
glioblastoma cell lines, such as T98G, LN229, and LN18 (Fig. 2D). We found that APC- and biotin-conjugated
anti-MET antibodies strongly induced MET and AKT phosphorylation, as compared to the HGF control, in all
these glioblastoma cell lines (Fig. 2D). These observations suggest that the anti-MET antibodies can effectively
activate MET in a variety of glioblastoma cell lines.

Activation of the MET signaling and clustering by APC- or biotin-conjugated anti-MET antibodies requires the RTK activity of MET. The activation of MET by the addition of the APC- or

biotin-conjugated anti-MET antibodies in serum-starved cells represents a ligand-independent activation of the
MET receptor on the plasma membrane. The binding of these conjugated antibodies to MET is likely to stimulate the cross-phosphorylation of the MET receptor proteins on the plasma membrane, which is reminiscent
of its natural ligand, HGF, binding to the receptor. To verify that the activation of MET by these conjugated
antibodies is dependent on the activity of the MET receptor, we used crizotinib26, a relative specific tyrosine
kinase inhibitor (TKI) of MET. Our studies showed that inhibition of the MET RTK activity by crizotinib indeed
effectively blocked the ligand-independent MET activation and MET signaling to AKT by the biotin-conjugated
or APC-conjugated anti-MET antibodies, in a manner similar to the crizotinib’s effect on the HGF-dependent
activation process (Fig. 3A–C).
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Figure 2. The MET receptor is activated by HGF, or APC- or Biotin-conjugated anti-MET antibodies. (A)
Serum-starved U373-MG cells were treated either with HGF (50 ng/ml) for 7 minutes or left untreated (-HGF)
as indicated. The cells were directly lysed in SDS buffer and proteins were detected by Western blotting with
antibodies for the Y1234/Y1235-phosphorylated MET (p-MET, Y1234/5), total MET, phosphorylated AKT (pAKT), total AKT, or actin (loading control), as indicated. (B) Serum-starved U373-MG cells were left untreated,
or treated with APC-conjugated mouse IgG control antibody or APC-conjugated mouse monoclonal anti-MET
antibody (each at 1 μg/ml) for 7 minutes. Cells were directly lysed in SDS buffer and proteins were detected by
Western blotting with antibodies as in panel A. (C) The same as panel B except that the Biotin-conjugated goat
control IgG or Biotin-conjugated goat anti-MET antibodies (each at 2 μg/ml) were used. (D) Serum-starved
human glioblastoma cells T98G, LN229, and LN18 cells were treated with HGF or biotin-conjugated IgG or
biotin-conjugated anti-MET antibodies as in panel A and C, or left untreated. The proteins were detected by
Western blotting with antibodies as in panel A.

The clustering of the phosphorylated MET protein on the plasma membrane by the APC- or biotin-conjugated
anti-MET antibodies in the serum-starved cells is likely due to the actions of the activated MET proteins on the
plasma membrane (Fig. 1). We, therefore, also examined whether the formation of the MET clusters after the
addition of the APC- or biotin-conjugated anti-MET antibodies required the kinase activity of MET RTK. Our
studies revealed that the formation of clustered and activated MET proteins on the plasma membrane was abolished by the pre-treatment of cells with crizotinib in U373-MG cells, using cells treated with HGF as controls
(Figs 3D,E; S2A). Although crizotinib is often used as an inhibitor for MET25, the chemical is also known to
inhibit ALK or ROS-1 RTKs26. We therefore further tested the effects of other MET inhibitors, JNJ-3887760527 or
SGX-52328, which are more selective MET TKIs than crizotinib. Our data showed that the MET activation and
clustering induced by HGF or by anti-MET antibodies was each potently inhibited by JNJ-38877605 (Fig. 3C–E)
or SGX-523 (Fig. S2B,C), suggesting that the kinase activity of MET was involved in the antibody-mediated
receptor clustering process. Together, our results indicate that the bivalent anti-MET antibodies can activate MET
RTK which in turn triggers the receptor clustering, in a manner similar to that of HGF binding to the MET
receptor.

The pre-treatment of cells with biotin-conjugated anti-MET antibodies abolishes the response
to HGF. Our analysis of the time course of the MET protein have shown that addition of the biotin-conjugated

anti-MET antibodies led to the disappearance of the MET protein on the cell surface, following its transient activation on the plasma membrane (Fig. 1B,D). We designed a series of experiments to examine the fate of the receptors that are bound by the anti-MET antibodies, by testing if cells could still respond to HGF after pre-treatment
with the biotin-conjugated anti-MET antibodies. In our control experiments, we pre-treated the serum-starved
U373-MG cells with HGF for 7 minutes (1st treatment), which induced the MET activation and receptor clustering on the plasma membrane (Fig. 4A). We next removed the unbound HGF by washing cells with the PBS buffer
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Figure 3. Activation of the MET receptor by HGF or anti-MET antibodies requires the MET RTK activity.
(A) Serum-starved U373-MG cells were treated with the MET kinase inhibitor, crizotinib (1 μM) (lane 4–6) or
DMSO (lane 1–3) for 3 hours. The cells were then treated either with biotin-conjugated anti-MET antibodies
or biotin-conjugated IgG (each at 2 μg/ml) for 7 minutes, or left untreated, as indicated. The cells were directly
lysed in SDS buffer and proteins were detected by Western blotting with antibodies for the Y1234/Y1235phosphorylated MET (p-MET, Y1234/5), total MET, phosphorylated AKT (p-AKT), total AKT, and actin
(loading control), respectively, as in Fig. 2A. (B) The same as in panel A except that the APC-conjugated
mouse monoclonal anti-MET antibodies or mouse IgG control antibodies (each at 1 μg/ml) were used. (C)
Serum-starved U373-MG cells were treated with dimethyl sulfoxide (DMSO) vehicle control (lane 1, 2), or
with the MET kinase inhibitors crizotinib (1 μM) (lane 3, 4) or JNJ-38877605 (1 μM) (lane 5,6) for 3 hours.
Cells were then treated with or without HGF (50 ng/ml) for 7 minutes as indicated. The cells were directly lysed
in SDS buffer and proteins were detected by Western blotting with indicated antibodies. (D) Serum-starved
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U373-MG cells were treated with the MET kinase inhibitors, crizotinib, JNJ-38877605 or DMSO as in panel C.
Cells were stimulated with or without HGF (50 ng/ml) for 7 minutes and were subsequently fixed and stained
with rabbit antibody against Y1234/Y1235-phosphorylated MET (red) for the activated MET protein and
with the Alexa Fluor 488 pre-conjugated anti-MET antibody for total MET protein (green), and bright field
for the contrast phase. Cells were also counter stained with DAPI for nuclei. MET receptor clusters (patches)
are indicated by arrows. (E) Serum-starved U373-MG cells were treated with the MET inhibitors crizotinib,
JNJ-38877605 or dimethyl sulfoxide (DMSO) as in panel C. The live serum-starved U373-MG cells were then
treated with biotin-conjugated goat anti-MET antibodies (2 μg/ml) or biotin-conjugated goat IgG antibodies
(2 μg/ml) (control) for 7 minutes. The cells were then fixed and stained with streptavidin (labeled with Brilliant
Violet 421) for biotin-conjugated antibodies (purple) and the rabbit anti-Y1234/1235-phosphorylated MET
antibodies (followed by secondary antibodies conjugated to the Alexa Fluor 647) for the activated MET protein
(red), and with the Alexa Fluor 488 pre-conjugated anti-MET antibody for total MET protein (green). MET
receptor clusters (patches) are indicated by arrows. Scale bars in (D,E), 20 μm.

and re-incubated the cells in the serum-starvation medium for 30 minutes (recovery time) to allow the endocytosis and removal of the activated MET proteins on the cell surface during the 1st HGF treatment. We then re-added
HGF the second time for 7 minutes (2nd treatment) to the cells that have been received the 1st HGF treatment,
and examined the response of these cells to form the MET clusters (Fig. 4A,C). Our studies revealed that the 2nd
HGF addition can still stimulate the cluster formation of the phosphorylated and activated MET proteins in the
plasma membrane in cells received the 1st HGF treatment (Fig. 4A). Our Western blotting analysis also revealed
that the 2nd HGF addition promotes the similar levels of the Y1234/Y1235-phosphorylated MET protein in the
cells that have received the 1st HGF treatment (Fig. 4C), suggesting that the prior HGF treatment did not abolish
the responsiveness of the serum-starved cells to the second HGF stimulation.
However, there is a striking difference in the response to the HGF treatment (2nd treatment) if the cells had
received the prior or 1st treatment of the biotin-conjugated anti-MET antibodies (Fig. 4B,C). In these experiments, we similarly pre-treated serum-starved cells with the biotin-conjugated anti-MET antibodies for 7 minutes
(1st treatment) and removed the unbound antibodies by extensive washing. The antibody-pretreated cells were
next incubated in the serum-starvation medium for 30 minutes (recovery time), which greatly eliminated the
activated MET protein on the cell surface (Fig. 4B). Cells were then exposed to HGF (2nd treatment) and the
cluster formation of the activated and phosphorylated MET protein was monitored. We found that pre-treatment
of cells with the biotin-conjugated anti-MET antibodies greatly dampened the responsiveness of the cells to form
clusters when exposed to HGF (Fig. 4B). Unlike the 1st treatment of HGF, we found that 1st treatment of the
biotin-conjugated anti-MET antibodies greatly reduced the response of cells to HGF (2nd treatment) to activate
MET phosphorylation, as revealed by Western blot analysis (Fig. 4C). We also monitored the fate of the anti-MET
antibodies after a 7-minute exposure to cells (1st treatment), and found that the antibody-marked MET proteins were accumulated in the lysosomes following a 30-minute chase (Fig. S3). These studies indicate that the
biotin-conjugated anti-MET antibodies pre-treatment caused the MET proteins to be routed to the lysosomes,
consequently deplete the cell surface MET and prevent cells to further respond to the HGF stimulation.

Pretreatment of biotin-conjugated anti-MET antibodies blocked subsequent AXL phosphorylation. We have recently found that HGF-induced MET clustering involves a complex formation of MET and

AXL, another important RTK in glioblastoma22. The co-clustering of MET and AXL is accompanied by AXL
phosphorylation at Tyr-779 and AXL activation22. We wondered if the anti-MET antibodies induced MET clustering also involves AXL. We found that treatment of cells with the biotin-conjugated antibodies induced the
phosphorylation of Tyr-779 in AXL and the phosphorylated AXL was co-clustered with MET (Figs 5A; S4A).
Similar events were also observed when cells were exposed to APC-conjugated anti-MET antibodies (Fig. S4B).
These observations suggest that the anti-MET antibodies induced the early MET signaling events similar to that
of HGF. However, when we performed a sequential HGF treatment experiments, the anti-MET antibodies pretreated cells behaved very differently from the HGF-pretreated cells (Fig. 5B). While cells pretreated with HGF
could again induce AXL Tyr-779 phosphorylation and AXL co-clustering, the cells pretreated with anti-MET
antibodies failed to respond to the subsequent 2nd treatment of HGF and could no longer induce AXL-MET
co-clustering and AXL phosphorylation (Figs 5B; S4C). Western blot analysis confirmed that pre-treatment with
anti-MET antibodies blunted the subsequent HGF-induced AXL phosphorylation at Tyr-779, while control cells
pretreated with HGF responded to subsequent HGF addition and effectively induced AXL phosphorylation
(Fig. 5C). These experiments demonstrate that pre-treatment of anti-MET antibodies can effectively block the
subsequent HGF-mediated AXL co-activation in these cancer cells, and such effects can be detected within less
an hour following a 7-minute antibody exposure.

The biotin-conjugated anti-MET antibodies trigger MET proteins degradation. To determine the
response of the MET protein to the ligand-dependent and ligand-independent activation stimuli, we measured
the time course of a continuous treatment of serum-starved cells with HGF or the biotin-conjugated anti-MET
antibodies (Fig. 6). We found that HGF stimulated rapid phosphorylation of the MET protein, reaching the peak
level around 15 minutes after its addition to the serum-starved cells (Fig. 6A). Continued treatment of HGF for
various time (30, 60, and 120 minutes) mostly maintained the total MET protein levels, with a partial reduction of
the activated and phosphorylated form of MET at later time points. As shown by quantification in Fig. 6B,C, HGF
treatment for 120 minutes did not significantly affect the total MET protein levels, although there is a gradual
reduction of the phosphorylated MET protein levels. Furthermore, a continued exposure to HGF up to 24 hours
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Figure 4. Pre-treatment of the serum-starved cells with the biotin-conjugated anti-MET antibodies renders
the cells refractory to the subsequent HGF stimulation. (A) U373-MG cells were serum-starved for 3 hours.
Cells were pulse-treated (1st treatment) with PBS (phosphate buffered saline, control) or HGF (50 ng/ml) for
7 minutes, washed extensively with warm PBS buffer, and then incubated in the serum-starvation medium for
30 minutes to recover. They were then re-stimulated (2nd treatment) with HGF or PBS (as control) for another
7 minutes. Cells were fixed and immunostained with the anti-Y1234/1235-phosphorylated MET antibodies.
MET receptor clusters (patches) are indicated by arrows. (B) Serum-starved U373-MG cells were pulse-treated
(1st treatment) with the Biotin-conjugated anti-MET antibodies or biotin-conjugated IgG (each at 2 μg/ml) for
7 minutes, washed extensively with warm PBS buffer, and then incubated in the serum-starvation medium for
30 minutes to recover. Cells were then stimulated (2nd treatment) with HGF (50 ng/ml) or PBS (control) for
another 7 minutes. Cells were fixed and immunostained with streptavidin (pre-labeled with Brilliant Violet 421,
green) and anti-Y1234/1235-phosphorylated MET antibodies (secondary antibody conjugated with Alexa Fluor
647, red). MET receptor clusters (patches) are indicated by arrows. Scale bar in B, 20 μm. (C) Serum-starved
U373-MG cells were treated as in (A,B), with the 1st treatment being either HGF (50 ng/ml) or PBS control
(lanes 1–5) or alternatively with the biotin-conjugated anti-MET antibodies or the control IgG (each at 2 μg/ml)
(lanes 6–9), for 7 minutes, as indicated. Cells were washed extensively with warm PBS and then recovered in the
serum-starvation medium for 30 minutes. Cells were subsequently stimulated (2nd treatment) with HGF (50 ng/
ml) or PBS (control) for another 7 minutes, as indicated. Cells were lysed and the levels of the Y1234/1235phosphorylated MET and total MET proteins were analyzed by Western blotting with specific antibodies as
indicated.
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Figure 5. Pre-treatment of the serum-starved cells with the biotin-conjugated anti-MET antibodies caused
the activation of AXL refractory to the subsequent HGF stimulation. (A) Live serum-starved U373-MG cells
were treated with biotin-conjugated goat anti-MET antibodies or biotin-conjugated control IgG (each at 2
μg/ml) for 7 minutes. Cells were then washed, fixed and immunostained with the streptavidin-conjugated to
Brilliant Violet 421 to detect the biotin-conjugated antibodies (purple), a rabbit anti-Y779-phosphorylated
AXL antibody for the activated AXL protein (secondary antibody conjugated with Alexa Fluor 647, red), and
an anti-MET antibody pre-conjugated to Alexa Fluor 488 for total MET protein (green). (B) U373-MG cells
were serum-starved for 3 hours. Cells were pulse-treated (1st treatment) with the biotin-conjugated anti-MET
antibodies or control IgG (each at 2 μg/ml), PBS (control) or HGF (50 ng/ml) for 7 minutes, washed extensively
with warm PBS buffer, and then incubated in the serum-starvation medium for 30 minutes to recover. They
were then re-stimulated (2nd treatment) with HGF (50 ng/ml) or PBS (as control) for another 7 minutes.
Cells were fixed and immunostained with the anti-Y779-phosphorylated AXL antibody or with an anti-MET
antibody. MET receptor clusters (patches) are indicated by arrows. Scale bars in (A,B), 20 μm. (C) Serumstarved U373-MG cells were treated as in B, with the 1st treatment being either HGF or PBS control (lanes 1–4)
or alternatively with the biotin-conjugated anti-MET antibodies (2 μg/ml) (lane 7, 8) or control IgG control
(2 μg/ml) (lanes 5, 6), for 7 minutes, as indicated. Cells were washed extensively with warm PBS and then
recovered in the serum-starvation medium for 30 minutes. Cells were subsequently stimulated (2nd treatment)
with HGF (50 ng/ml) or PBS (control) for another 7 minutes, as indicated. Cells were lysed and the levels of
the Y1234/1235-phosphorylated MET and total MET proteins, anti-Y779-phosphorylated AXL antibody, total
AXL, phosphorylated AKT (p-AKT), total AKT, were analyzed by Western blotting with specific antibodies as
indicated.
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Figure 6. Ligand-independent activation of MET by the Biotin-conjugated anti-MET antibodies promotes
degradation of the MET protein. (A) Serum-starved U373-MG cells were treated either with HGF (50 ng/ml)
or PBS (control), alternatively, with the biotin-conjugated anti-MET antibodies or control IgG (each at 2 μg/ml)
for various time points as indicated. The cells were directly lysed in SDS buffer and the protein levels of Y1234/
Y1235-phosphorylated MET (p-MET, Y1234/5) and total MET proteins were detected by Western blotting
with respective antibodies. Actin is used as the loading control. Shown is a representative set of blots from three
independent repeats. (B) A quantification of p-MET protein levels in cells treated with HGF or with anti-MET
antibodies using data from panel A. The relative p-MET protein levels were first normalized to the actin as
loading control, and then calculated using the p-MET levels at 15 min after HGF treatment as the reference
point (1.0). Data of quantitation are shown, with the mean and standard deviation (S.D.) for error bars derived
from three independent repeats. (C) A quantification of total MET protein levels in cells treated with HGF or
anti-MET antibodies using data from panel A. The relative total MET protein levels were first normalized to
the actin as loading control, and calculated using the MET protein levels at the 0 min time points under each
condition as the reference point (1.0). Data of quantitation are shown, with the mean and standard deviation
(S.D.) for error bars derived from three independent repeats. (D) Serum-starved U373-MG cells were treated
either with HGF (50 ng/ml) or the biotin-conjugated anti-MET antibodies (2 μg/ml), or with corresponding
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PBS and the normal IgG controls, for extended time points as indicated. The protein levels of total MET
proteins were detected by Western blotting with respective antibodies as described in panel A. Relative levels of
total MET proteins during each treatment were quantified as in panel B. Shown is a representative set of blots
from three independent repeats. (E) Serum-starved U373-MG cells were pulse-treated (7 minutes treatment)
with either HGF (50 ng/ml), the biotin-conjugated anti-MET antibodies (2 μg/ml) or PBS (as control) as
indicated. The cells were washed and then incubated in the starvation media to recover for the indicated times
before harvesting. The protein levels of total MET protein were detected by Western blotting with anti-MET
antibodies. Actin is used as the loading control. Relative levels of total MET proteins during each treatment at
various time points were quantified as in panel B. Shown is a representative set of blots from three independent
repeats. (F) Serum-starved U373-MG cells were pulse-treated for 7 minutes with either HGF (50 ng/ml), the
biotin-conjugated anti-MET antibodies (2 μg/ml), or left untreated (control). The cells were washed extensively
with warm PBS to remove the unbound HGF or the antibodies, and then incubated in the starvation media
for recovery for the indicated times. Cells were then fixed and immunostained with anti-MET antibodies.
Arrowheads indicate the presence of MET protein on the plasma membrane. Scale bars, 20um.

caused minor changes in the levels of total MET proteins (Fig. 6D). Thus, prolonged treatment of HGF does not
significantly affect the levels of total MET proteins (Fig. 6A,C,D).
In sharp contrast, however, the biotin-conjugated anti-MET antibodies induced MET protein phosphorylation with a similar kinetics as that of HGF, although slightly less potent (Fig. 6A,B). Continued exposure to the
biotin-conjugated anti-MET antibodies led to a steady and faster decline of the phosphorylated form of MET
protein and a decrease in the levels of the total MET protein starting at 30 minutes. The total MET protein, as well
as the phosphorylated MET, completely disappeared by 120 minutes, in the antibody-treated cells (Fig. 6A–C).
No significant effects on the levels of total MET protein were observed in cells treated with the biotin-conjugated
control IgG (Fig. 6A). Similar effects were observed when cells were continuously treated with HGF or anti-MET
antibodies for 4–24 hours (Fig. 6D).
We also examined the effects of pulse or transient stimulation with HGF or with anti-MET antibodies on the
levels of total MET proteins, In these experiments, serum-starved cells were stimulated with HGF or anti-MET
antibodies for 7 minutes (pulse), washed and then incubated in the fresh serum-starvation medium for various
time (chase) (Fig. 6E). In cells that had been exposed to a 7-minute pulse of anti-MET antibodies, there was a
rapid decline of the total MET protein levels (Fig. 6E). By 60 minutes of the chase, the level of total MET protein
were reduced by 67%, and stayed at about this level through 240 minutes of the chase (Fig. 6E). The remaining
33% of the MET proteins, which were resistant to the anti-MET antibodies induced degradation, likely represented the intracellular pool of the MET proteins at the time before the exposure to antibodies (0 minute). In contrast, there was little reduction of total MET protein levels during the 240 minutes chase after a pulse-treatment
with HGF (Fig. 6E), suggesting that the HGF-bound receptors can mostly recycle back to the cell surface. Using
immunostaining, we found that in the cells that were pulse-stimulated with HGF, the MET protein was detected
on the cell surface by 30 minutes of the chase, but in the cells that were pulse-stimulated with anti-MET antibodies, no cell surface MET protein was detected even after 120 minutes of the chase (Fig. 6F). Together, these
observations suggest that while the MET RTKs activated by HGF can reappear on the cell surface, likely mediated
through a recycling process, but the MET RTKs bound by the anti-MET antibodies were targeted to degradation.

The biotin-conjugated anti-MET antibodies induce a proteome-sensitive and lysosomedependent proteolysis of MET protein. In normal cells, binding of HGF to MET is known to trigger

mono-ubiquitination of the receptor proteins, with the mono-ubiquitination modification serving as a sorting
signal to sort the marked receptors to multivesicular bodies (MVBs)29–31. MVBs can further mature into late
endosomes, which then fuse with lysosomes, leading to degradation of the mono-ubiquitinated receptors in the
lysosomes32. Interestingly, sorting of MET RTK in MVBs is also sensitive to proteasome inhibitors, although the
exact mechanism remains unclear29–31. To examine the cause of MET protein disappearance in serum-starved
cells treated with the biotin-conjugated anti-MET antibodies, we examined if the MET protein degradation could
be prevented by MG-132, an inhibitor of the 26S proteosome that targets poly-ubiquitinated proteins for degradation33, or by bafilomycin A1 (BAF)34, a specific inhibitor of vacuolar-type H(+)-ATPase that inhibits the acidification of lysosomes and consequently blocks protein degradation in lysosomes. Serum-starved cells were treated
with biotin-conjugated anti-MET antibodies or treated with HGF as control. After 7 minutes, BAF or MG-132
were added to the medium and incubated for further 2 hours (Fig. 7A). We found that the presence of MG-132
completely restored the MET protein levels in the cells treated with the biotin-conjugated anti-MET antibodies.
In addition, BAF also partially stabilized the MET protein level in the cells treated with the biotin-conjugated
anti-MET antibodies (Fig. 7A). As control, in the cells treated with HGF, a slight reduction (~5%) of MET protein levels following HGF treatment was observed, and such reduction was also prevented by MG-132 or BAF
(Fig. 7A). Similar to the effects observed in cells treated with the biotin-conjugated goat anti-MET antibodies, MG-132 and BAF each rescued, or partially rescued, respectively, the MET levels in cells treated with the
APC-conjugated mouse anti-MET antibodies (Fig. 7B). Similar effects of MG132 and BAF on preventing MET
protein degradation induced by anti-MET antibodies were observed in several other GBM cells lines, including
LN229, LN18 and TG98 (Fig. 7C). The anti-MET antibodies thus induced a proteasome-sensitive, and lysosome
dependent, degradation of MET proteins that has been previously described for the HGF-induced degradation
of MET proteins in other cells29–31, however, in U373-MG cells, HGF was completely ineffective in triggering
down-regulation of MET proteins.
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Figure 7. Biotin-conjugated anti-MET antibodies promote degradation of the MET protein in a proteasomesensitive manner. (A) Serum-starved U373-MG cells were treated either with HGF (50 ng/ml) (lanes 4–6) or the
biotin-conjugated anti-MET antibodies (2 μg/ml) (lanes 10–12), or with the corresponding controls PBS (lanes
1–3) or the control IgG (2 μg/ml) (lanes 7–9), for 7 minutes as indicated. To each set of the cells, either DMSO
(control), MG-132 (10 μg/ml), or bafilomycin A1 (BAF, 100 nM) were then added and incubated for further
2 hours. The cells were lysed in SDS buffer and the protein levels of total MET protein were detected by Western
blotting with anti-MET antibodies. Actin is used as the loading control. Relative levels of total MET proteins
during each treatment were quantified normalized to the actin load control, and then calculated using the MET
protein levels in the PBS/DMSO control sample (lane 1) as the reference point of 1.0. Data of quantitation is
obtained from three independent repeats, and a set of blots from one of these experiments is shown. (B) Serumstarved U373-MG cells were treated either with APC-conjugated anti-MET antibodies (1 μg/ml, lanes 4–6) or
control IgG (1 μg/ml, lanes 1–3) for 7 minutes as indicated. Cells were then treated with DMSO, MG-132 or BAF,
as in panel A, and processed similarly as in panel A. Relative levels of total MET proteins during each treatment
were quantified, normalized to the actin load control, and then calculated using the MET protein levels in the
IgG-APC/DMSO control sample (lane 1) as the reference point of 1.0. Data of quantitation is obtained from three
independent repeats, and a set of blots from one of these experiments is shown. (C) Serum-starved LN229, LN18
and T98G cells were treated either with biotin-conjugated anti-MET antibodies (2 μg/ml) (lanes 5–7) or HGF
(50 ng/ml) (lanes 1–3) or left untreated (lane 4) for 7 minutes as indicated. Cells were then treated with DMSO,
MG-132 or BAF, as in panel A. The cells were lysed in SDS buffer and the protein levels of total MET protein were
detected by Western blotting with anti-MET antibodies. Actin is used as the loading control.

The biotin-conjugated anti-MET antibodies inhibit cell migration. Because the anti-MET antibod-

ies tested above trigger an efficient MET protein degradation, we wondered if exposure of cells to these antibodies
can efficiently suppress the HGF-mediated biological events. Since the MET receptor plays a key role in cell
migration and invasive growth of various cancer cells, we examined the potential effects of anti-MET antibodies
on cell migration. In actively growing U373-MG cells, treatment of cells with the biotin-conjugated anti-MET
antibodies for 15 hours potently suppressed the cell migration in a wound-healing assay, as compared to that
of the biotin-conjugated control IgG (Fig. 8A). Western blot analysis confirmed that the MET protein levels
are effectively down-regulated during the antibody treatment process (Fig. 8A). We also examined the effects
of HGF and anti-MET antibodies in the serum-starved cells. While exposure to HGF for 24 hours significantly
stimulated cell migration, similar exposure to the biotin-conjugated anti-MET antibodies could not stimulate
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Figure 8. Biotin-conjugated anti-MET antibodies inhibited cell migration. (A) U373-MG cells were seeded
on the plate and cultured in complete medium for 16 hours. A sterile 20 μl tip was used to scrape the cells to
make a wound. The cells were washed with warm PBS to remove floating cells and replaced with fresh complete
medium. The biotin-conjugated anti-MET antibodies or biotin-conjugated control IgG (each at 2 μg/ml) were
added to the cells for additional 15 hours. The live cells were photographed (A). The cells migrated into the
wound area at the 15 hour time point were quantified from 6 independent fields and integrated, and the means
(with S.D.) from a duplicate set of samples were calculated. Statistical analysis was conducted (compared to
IgG control) (statistical significance ***p < 0.001). The cells were then lysed in SDS buffer and the total levels
of MET protein and actin (loading control) were examined by Western blotting. (B,C,E). U373-MG cells were
seeded on the plate for 16 hours and then serum-starved for additional 9 hours. A scrape wound was made
on each plate as in panel A (time point 0 hour). To each plate, HGF (50 ng/ml) or PBS (control) was added;
alternatively, biotin-conjugated control antibodies (IgG-Biotin) or anti-MET antibodies (α-MET-Biotin)
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(each at 2 μg/ml), either alone or together with HGF, were added to the media; and cells were further incubated
for 24 hours. The live cells were photographed at the time point 24 hours. The cells migrated into the wound
area at the 24 hour time point were quantified as in panel A, and normalized to that when cells were treated with
PBS and IgG control, and the means (with S.D.) from a duplicate set of samples were calculated and shown in
panel C. Statistical analysis was conducted for each indicated pair (statistical significance ***p < 0.001). The
U373-MG cells were lysed and the total levels of MET protein and actin (loading control) were examined by
Western blotting (panel E). (D,F) The LN229 cells were treated in the same way and quantified as in panel B and
C. Statistical analysis was conducted (compared to PBS and IgG control) (statistical significance ***p < 0.001).
The cells were then lysed in SDS buffer and the total levels of MET protein and actin (loading control) were
examined by Western blotting (panel F).

cell migration. Rather, the antibodies in fact reduced the basal level of cell migration as compared to that of the
biotin-conjugated IgG control (Fig. 8B,C). Notably, addition of both biotin-conjugated anti-MET antibodies and
HGF to the serum-starved cells for 24 hours significantly blocked the stimulation activity of HGF on cell migration, while no inhibitory effects were observed with the biotin-conjugated control IgG (Fig. 8B,C). Under these
conditions, the biotin-conjugated anti-MET antibodies markedly reduced the levels of total MET protein, even in
the presence of HGF (Fig. 8E). Similar inhibitory effects of the biotin-conjugated anti-MET antibodies towards
cell migration were also observed in other GBM cell lines, LN229, LN18 and T98G (Figs 8D,F; S5). Our studies
thus indicate that the biotin-conjugated anti-MET antibodies can be used to target MET protein for degradation
and block the biological activities of MET on cell migration in various GBM cells.

The biotin-conjugated or APC-conjugated anti-MET antibodies inhibit cancer cell invasion.

Glioblastoma cells are known to be highly invasive. To determine whether anti-MET antibodies affect such
invasiveness, we further examined the effects of these anti-MET antibodies on gliobastoma cell invasion, using
Transwells pre-coated with Matrigel (Fig. 9). We first assayed the effects of the anti-MET antibodies on cancer cell invasion when glioblastoma cells were cultured in the complete media. We have observed that the cancer cell invasion of both U373-MG and LN229 cells were effectively suppressed by either the biotin-conjugated
goat anti-MET antibodies or the APC-conjugated mouse anti-MET antibodies (Fig. 9A,B). Quantification of
the tumor cell invasion index showed that these antibodies can effectively reduce the cancer cell invasion index
by 40–60%, depending on the antibodies used. We also assayed the effects of these antibodies on HGF-induced
cancer cell invasion. Again, with both cell lines, we have observed that the biotin-conjugated anti-MET antibodies
can effectively block HGF-induced cancer cell invasion (Fig. 9C,D). Our data indicate that these anti-MET antibodies are biologically inhibitory to the MET signaling pathway for cancer cell invasion.

Discussion

In this report, we describe single cell-based assays to analyze the activation and subsequent processing of the
MET receptor in response to the binding of antibodies in glioblastoma cells. By using fluorescently tagged
anti-Met antibodies, we found that binding of anti-MET antibodies to the MET receptor induced the transient
formation of a highly polarized receptor cluster on the plasma membrane, in a manner similar to the events when
the receptors were bound by their cognate ligand, HGF (Fig. 1). However, while the HGF-bound MET receptors
were internalized and then recycled to cell surface, as revealed by the limited degradation of MET following
the HGF treatment, the antibody-bound MET receptors were rapidly degraded. A short exposure (7 minutes)
to the anti-MET antibodies was sufficient to induce the degradation of the activated MET protein on the cell
surface during the subsequent chase period (30–60 minutes), while a longer exposure (2 hours) to the antibodies
led to the near complete depletion of the entire cellular pool of MET proteins (Fig. 6). We also found that the
antibody-MET complexes were degraded through a process that is highly sensitive to the proteasome inhibitor
MG-132 (Fig. 7). It is also partially sensitive to a proton pump inhibitor bafilomycin (Fig. 7). It is possible that the
binding of MET with antibodies altered the highly efficient recycling pathway for MET proteins in glioblastoma
cells, leading to degradation of the receptor proteins. The exact mechanisms by which the antibody-bound MET
proteins are preferentially degraded await further studies.
We have recently found that HGF binding caused the formation of the MET-AXL complex and co-clustering
of these receptors on the plasma membrane22. In the current study, we have tested two commercially available anti-MET antibodies, a goat polyclonal antibody (biotin-conjugated) and a mouse monoclonal antibody
(APC-conjugated), which are likely to recognize different epitopes in the MET extracellular domain. However,
both antibodies can efficiently induce the rapid MET-AXL co-clustering and the phosphorylation and activation
of both MET and AXL (Figs 1 and 5). It remains unclear whether the MET-AXL co-clustering and AXL phosphorylation induced by the anti-MET antibodies is mediated through the formation of the MET-MET homodimers which then lead to the formation of the MET-AXL heterodimers or whether these antibodies directly
activate the MET protein in the MET-AXL heterodimer complex through binding to MET. Nevertheless, both
biotin-conjugated and APC-conjugated antibodies caused an altered processing of the activated MET proteins,
leading to the rapid degradation of the receptors, instead of recycling of these receptors when binding to HGF
(Figs 6 and 7). These observations suggest that these two types of antibodies may induce a common structural or
conformation change in MET to alter the receptor trafficking routes.
The MET RTK is often over-expressed in human cancers, and the activation of MET RTK is associated with
aggressive cancer cell growth, metastasis and resistance towards a variety of anti-cancer drugs3,4,6. How to effectively target the over-expressed or abnormally activated MET proteins is an important question for developing
novel anti-cancer therapeutics. Several anti-HGF antibodies are in the pre-clinical or clinical development, and
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Figure 9. Biotin-conjugated anti-MET antibodies inhibited cell invasion. (A) An equal number of U373-MG
cells were seeded to the top chamber of the Boyden chamber precoated with Matrigel. Cells were incubated in
the complete medium and the bottom chamber also contained complete medium supplemented with biotinconjugated control IgG or anti-MET antibodies (each at 2 μg/ml), or with APC-conjugated control IgG or antiMET antibodies (each at 1 μg/ml). After 24 hours, cells that migrated to the bottom chamber (invaded through
Matrigel) were stained, imaged by an EVOS light microscope, and quantified using the ImageJ software.
Assays were performed in triplicates, and the means (with S.D.) are shown at the bottom. Statistical analysis
was conducted (compared with the corresponding control in each subgroup) (***p < 0.001, **p < 0.01). (B)
LN229 cells were assayed, similar to that described in panel A, except that the cells were allowed to invade for
32 hours. (C) U373-MG cells were starved for 9 hours and the equal number of cells were then seeded to the
top chamber of the Boyden chamber with serum-starvation medium, and the bottom chamber contained the
serum-starvation medium supplemented with HGF (50 ng/ml), PBS, anti-MET antibodies or control IgG as in
panel A, or combination of HGF and antibodies as indicated. Invasion assays were carried out for 24 hours. The
assay plates were then processed as in panel A and similarly quantified. Assays were performed in triplicates
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and the means (with S.D.) are shown on bottom. Statistical analysis was conducted (compared with the
corresponding control in each subgroup) (***p < 0.001, **p < 0.01). (D) LN229 cells were assayed, similarly
to that described in panel C, except that the cells were allowed to invade for 32 hours. Assays were performed in
triplicates, and the means (with S.D.) are shown on bottom. Statistical analysis was conducted (compared with
the corresponding control in each group) (***p < 0.001, **p < 0.01).

these antibodies act by neutralizing the ligand for the receptor or preventing the ligand binding to the receptor15,16. Alternatively, several anti-MET monoclonal antibodies have been developed to block the interaction of
MET with HGF. Since one major concern is that bivalent antibodies may activate MET, substantial efforts were
aimed to identify the non-agonist antibodies such as the monovalent antibodies. One example is the one-armed
monovalent 5D5 antibody17–19, which binds to the monomeric form of MET. Although this antibody blocks the
binding of HGF to the receptor, a phase III clinical trial for this antibody has produced disappointing results due
to its lack of clinical efficacy35. A bivalent antibody that does not activate the RTK activity of MET, SAIT301,
was developed and reported to cause a CBL-independent downregulation of MET after an incubation of cells
with antibodies for 24 hours21. Another bivalent monoclonal antibody, LY2875358, was recently shown to possess a neutralizing activity against HGF through blocking the interaction between HGF and MET20. It was also
observed that LY2875358 caused a slow and lysosome-dependent degradation of MET, with 50% reduction of
the MET protein level occurred after 24 hours of incubation20. Contrary to the concern that bivalent antibodies
may activate the targeted RTKs, in this report, we found that glioblastoma cells have an unusual high activity
of HGF-induced MET receptor recycling with very few MET molecules get downregulated after HGF stimulation. Treatment of these cancer cells with the bivalent anti-MET antibodies induces only a transient activation
of MET RTK activities. What follows is an altered intracellular processing of the MET protein through a novel
ubiquitin-dependent degradation process involving lysosomes that causes the rapid depletion of the near entire
pool of MET proteins. Consequently, these anti-MET bivalent antibodies are biologically inhibitory for cancer
cell migration and invasion. Our studies suggest that development of bivalent anti-MET immuno-reagents may
hold a promise to target and remove the MET proteins from glioblastoma cells or other cancer cells that possess
high HGF-induced recycling activity of MET.

Methods

Cells, antibodies, and reagents. Human glioblastoma cell lines U373-MG, T98G, LN229 and LN18 were

purchased from American Type Culture Collection (ATCC). Recombinant human HGF was from Invitrogen/
Thermo Fisher. Antibodies against MET, including goat anti-MET antibody (biotin-conjugates, #BAF358), and
mouse monoclonal anti-MET antibody (APC-conjugate, clone #95106, #FAB3528P), and control goat IgG (biotin-conjugates) and control mouse IgG (APC-conjugate), antibodies against MET (goat, #AF276), phosphorylated AXL (p-779-AXL, rabbit, #AF2228) were from R&D Systems. Rabbit antibodies against AXL, MET, Y1234/
Y1235-phosphorylated MET, phosphorylated AKT (at S473, recognizing all AKT isoforms, Cat. #9272), and antiMET rabbit monoclonal antibody (clone D1C2, Alexa Fluor 488 conjugate, Cat. #8494) were obtained from Cell
Signaling Technology. Chemicals, MG-132 and bafilomycin, were from Sigma-Aldrich. Secondary antibodies,
including the Alexa Fluor 488-conjugated goat anti-mouse IgG, Alexa Fluor 647-conjugated goat anti-mouse IgG
and Alexa Fluor 647-conjugated goat anti-rabbit IgG antibodies were from Jackson Immunologicals. Brilliant
Violet 421 or 605-conjugated streptavidin was from BioLegend. The CellTiter 96 AQueous One Solution Kit
was from Promega and the Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit was from Invitrogen/Thermo
Fisher. For tyrosine kinase inhibitors of MET, crizotinib was obtained from Cell Signaling Technology; JNJ38877605 and SGX-523 were obtained from Selleck Chemicals. Boyden chambers with 8 μm pores were from
Costar (Cambridge, MA), and the growth factor-reduced Matrigel was from BD Biosciences. Differential Quik
Stain Kit was obtained from Electron Microscopy Sciences.

Cell lysis and Western blot analysis. Cells were lysed in lysis buffer containing 50 mMTris (pH 7.4),
150 mM NaCl, 1% Triton-X-100, 0.1% SDS, supplemented with 5 mM NaF, 1 mM Na3VO4, and 1X complete
protease inhibitor (Roche, Indianapolis, IN). Western blotting was conducted as previously described36.
Immunostaining and fluorescence microscopy.

U373-MG cells were serum-starved for 3 hours, and
the starved cells were then stimulated with or without HGF (50 ng/ml), APC-conjugated mouse monoclonal
anti-MET antibody (1 μg/ml) and biotin-conjugated anti-MET antibody (2 μg/ml) for 7 minutes before fixation.
Immunofluorescence experiments were conducted as described23. Briefly, cells were fixed and permeabilized with
Fixation and Permeabilization Solution (BD Biosciences), blocked with goat serum, incubated with primary antibodies and then secondary antibodies in phosphate-buffered saline (PBS) containing 0.05% Tween 20 and 7%
goat serum. Images were acquired using a Nikon A1R confocal laser scanning microscopy system equipped with
the NIS-Elements Advance Research software with 20x objective (NA 0.8). For double or triple immunostaining,
fluorescence were obtained after excitation with laser light of 405 nm, 488 nm and 640 nm to capture images for
Brilliant Violet 421 (laser 405), Alexa Fluor 488 and Alexa Fluor 647, respectively, and these fluorophores have
minimal fluorescence bleed-throughs. Exposure settings were kept constant for all conditions within each set
of experiments. The captured images were further analyzed and quantified by using the NIS Elements Viewer
software.

Wound healing assay.

U373-MG cells were seeded on the plate and cultured for 16 hours. A sterile 20 μl
tip was used to scrape the cells to make a wound. The cells were washed twice with warm PBS to remove floating
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cells. The biotin-conjugated anti-MET antibody or Biotin-conjugated IgG (each at 2 μg/ml) were added to the
cells for additional 15 hours or longer, depending on the specific cell lines. For cells to be treated with HGF or
anti-MET-biotin antibody stimulated assay, cells were starved for 9 hours, then stimulated for 24 hours with HGF
(50 ng/ml) or anti-MET antibodies (2 μg/ml) or the corresponding controls. Cells were photographed using the
EVOS XL Core microscope system with 20x objective and the cells migrated into the wound area were quantified
using the Image J software37. For each condition, cells were counted from 6 independent fields and integrated. All
experiments were done in duplicates.

Cell invasion assay. Cell invasion assays were performed using Boyden chambers with 8 μm pores, coated
with the growth factor-reduced Matrigel diluted in Dulbecco’s modified Eagle’s medium. Cells were detached
by trypsin and washed once with starvation medium (Dulbecco’s modified Eagle’s medium, 0.5% fetal bovine
serum). Twenty thousand cells were seeded in the upper chamber for each condition in starvation medium, and
cells were allowed to invade for 24 hours toward the lower chamber containing starvation medium supplemented
with HGF (50 ng/ml) or PBS or IgG or anti-MET antibodies (2 μg/ml for biotin-conjugated antibodies, 1 μg/ml
for APC-conjugated antibodies), or in combinations of HGF + anti-MET antibodies or corresponding controls.
For cell invasion assay in the complete medium, cells were seed on the upper chamber, and cells were allowed to
invade for 24 hours toward the lower chamber containing complete medium supplemented with IgG or anti-MET
antibodies. Cells were then fixed with 4% paraformaldehyde. Cells in the upper chambers were mechanically
removed using cotton swabs. Cells invaded into the lower chambers were then stained with the Differential Quik
Stain Kit (modified Giemsa stain, obtained from Electron Microscopy Sciences). Cells were imaged using an
EVOS XL Core system with 20x objective and quantified using the ImageJ software. For each condition, cells were
counted from 6 independent fields and integrated. All experiments were done in duplicates.
Statistics and bioinformatics. Quantitative data are expressed as the mean ± S.D. (S.D., standard deviation), normalized to the control condition, and plots were prepared using the GraphPad Prism 5 software.
Statistically significant differences between means were determined using a two-tailed equal-variance Student’s
t-test38. Different data sets were considered to be statistically significant when the p-value was 0.001 (***), 0.01
(**) or <0.05 (*).
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